UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Conference Call March 24, 2023 4:30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Jeff Jones - Oppenheimer Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright & Co Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosci ...

Financial Performance - The company reported net losses of $108.4 million and $83.7 million for the years ended December 31, 2022, and 2021, respectively, with an accumulated deficit of $226.2 million as of December 31, 2022[537]. - The net loss for the year ended December 31, 2022, was $108.4 million, compared to a net loss of $83.7 million in 2021, reflecting an increase of approximately 29%[564]. - The company anticipates continuing to incur net losses for the foreseeable future, with no committed external source of funds[583]. - The company has incurred negative cash flows from operations since inception and expects this trend to continue[584]. Research and Development - Total research and development expenses increased to $87.7 million in 2022 from $58.5 million in 2021, with significant investments in VTX958 ($29.3 million), VTX002 ($23.4 million), and VTX2735 ($9.4 million)[556]. - The increase in research and development expenses included approximately $16.8 million for Phase 1 and Phase 2 trials for VTX958 and $12.1 million for the Phase 2 trial for VTX002[566]. - The company is actively enrolling in three Phase 2 trials for VTX958, with topline data expected in Q4 2023 for psoriasis and in 2024 for psoriatic arthritis and Crohn's disease[535]. - A Phase 2 trial for VTX002 in ulcerative colitis is ongoing, with topline data expected in the second half of 2023[535]. - The company plans to initiate a Phase 1 trial for VTX3232 in healthy volunteers in the first half of 2023[535]. Funding and Cash Flow - The company raised approximately $176.6 million in gross proceeds from a private placement of 5,350,000 shares of common stock in September 2022[540]. - The company received net proceeds of approximately $158.8 million from its initial public offering (IPO) in October 2021, selling 10,893,554 shares at $16.00 per share[541]. - In February 2023, the company issued 1,176,470 shares through an Open Market Sales Agreement, generating gross proceeds of $50.0 million[543]. - The net cash used in operating activities for the year ended December 31, 2022, was $98.8 million, primarily due to a net loss of $108.4 million[585]. - The net cash used in investing activities for the year ended December 31, 2022, was $74.9 million, mainly related to the purchase of $347.2 million in available-for-sale marketable securities[587]. - The net cash provided by financing activities for the year ended December 31, 2022, was $167.8 million, attributed to approximately $165.4 million in net proceeds from the issuance of common stock[589]. - The company expects its cash resources will fund operations into 2025 based on current estimates[580]. - Future funding requirements are anticipated to be substantial due to ongoing development activities and potential commercialization expenses[579]. - The company expects to finance its cash needs through a combination of equity, equity-linked, and debt financings, collaborations, and licensing arrangements[583]. Administrative Expenses - General and administrative expenses rose to $25.4 million in 2022 from $8.7 million in 2021, marking an increase of approximately 192%[568]. - General and administrative expenses are expected to increase further as the company expands operations and hires additional personnel[561]. - The company has incurred significant costs related to compliance with public company regulations, which are expected to continue[561]. Company Classification and Compliance - The company is classified as a "smaller reporting company" with a market value of stock held by non-affiliates below $700 million as of June 30, 2021, and annual revenue under $100 million for the fiscal year ended December 31, 2021[605]. - The company may continue to qualify as a smaller reporting company if the market value of stock held by non-affiliates remains below $250 million or annual revenue stays below $100 million in subsequent fiscal years[605]. - As a smaller reporting company, the company can present only the two most recent fiscal years of audited consolidated financial statements in its Annual Report on Form 10-K[605]. - Recent accounting pronouncements that may impact financial positions, results of operations, or cash flows are disclosed in Note 2 of the consolidated financial statements[606]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its classification as a smaller reporting company[608].

ventyx 017 BIOSCIENCES Corporate Presentation December 2022 Forward-Looking Statements 2 Ventyx Biosciences, Inc. ("we," "us," "our," "Ventyx," or the "Company") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: clinical development plans and related timing ...

017 ventyx BIOSCIENCES Corporate Presentation November 2022 Forward-Looking Statements 2 Ventyx Biosciences, Inc. ("we," "us," "our," "Ventyx," or the "Company") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: clinical development plans and related timing ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Swapnil Malekar - Piper Sandler Sam Slutsky - LifeSci Capital Emily Bodnar - H.C. Wainwright Alex Thompson - Stifel Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (St ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Yasmeen Rahimi - Piper Sandler Michael Yee - Jefferies Josh Schimmer - Evercore ISI Tiago Fauth - Credit Suisse Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Operator Thank you for standing by and welcome to the Venty ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State o ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Participants Yasmeen Rahimi – Piper Sandler Josh Schimmer – Evercore ISI Michael Yee – Jefferies Tiago Fauth – Credit Suisse Sam Slutsky – LifeSci Capital Jeff Jones – Oppenheimer Operator Good day, and thank you for standing by. Welcome ...